Definium Therapeutics, Inc.
DFTX- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- SEC CIK
- 0001813814
In the last 90 days, Definium Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 362 institutions reported holding it in 13F filings for Q2 2026, worth $5.35B in total; Duquesne Family Office is the only superinvestor holding it.
Q2 2023 vs. Q1 2023
How the institutions holding Definium Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Of which not filed for Q2 2023 | Q2 2023 | Change |
|---|---|---|---|---|
| Holders | 89 | 1 | 84 | −4 |
| Shares | 3.94M | 133 | 3.89M | −51.9K (−1.3%) |
| Value | $12.6M | $0 | $13.9M | +$1.34M (+10.6%) |
1 institution that held it in Q1 2023 haven't filed for Q2 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (8)
Institutions that held Definium Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Cresset Asset Management, LLC | 159,499 | $569.4K | 0.00% |
| Cornercap Investment Counsel Inc | 56,478 | $201.6K | 0.04% |
| Group One Trading, L.P. | 50,153 | $179.0K | 0.01% |
| Millennium Management LLC | 46,553 | $166.2K | 0.00% |
| Wolverine Trading, LLC | 10,770 | $37.3K | 0.00% |
| Moisand Fitzgerald Tamayo, LLC | 2,000 | $7.14K | 0.00% |
| Impact Partnership Wealth, LLC | 48 | $171 | 0.00% |
| Assetmark, Inc | 8 | $29 | 0.00% |
Sold out (12)
Institutions that held Definium Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Susquehanna International Group, LLP | 232,027 | $735.5K |
| Man Group plc | – | $59.0K |
| Citadel Advisors LLC | 14,790 | $46.9K |
| Prelude Capital Management, LLC | 12,400 | $39.3K |
| Tower Research Capital LLC (TRC) | 3,103 | $10.0K |
| Belpointe Asset Management LLC | 604 | $1.91K |
| Robbins Farley LLC | 28 | $89 |
| Advisory Services Network, LLC | 9 | $29 |
| Grey Fox Wealth Advisors, LLC | 6 | $19 |
| Ogorek Anthony Joseph | 16 | $0 |
| Front Row Advisors LLC | 133 | $0 |
| VitalStone Financial, LLC | 350 | $0 |
Not filed for Q2 2023 yet (1)
Institutions that held Definium Therapeutics, Inc. at the end of Q1 2023 and haven't filed a 13F for Q2 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Baldrige Asset Management LLC | 133 | $0 |